{"podcast":{"title":"Business Of Biotech","slug":"business-of-biotech-123501","podcast_index_feed_id":123501,"rss_url":"https://rss.buzzsprout.com/1011661.rss","website_url":"https://www.bioprocessonline.com/solution/the-business-of-biotech-podcast","image_url":"https://storage.buzzsprout.com/35u0bccu9j9xpr9zrrjias54otax?.jpg","author":"Ben Comer","episode_count":310,"summary":"The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.","last_synced_at":"2026-06-08T22:18:30.179389+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501"},"episodes":[{"title":"The Editors' Roundtable: A Midyear Look At The 2026 Life Sciences Industry","slug":"the-editors-roundtable-a-midyear-look-at-the-2026-life-sciences-industry","published_at":"2026-06-08T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/the-editors-roundtable-a-midyear-look-at-the-2026-life-sciences-industry","url":"https://www.buzzsprout.com/1011661/episodes/19288344-the-editors-roundtable-a-midyear-look-at-the-2026-life-sciences-industry.mp3","duration_seconds":5057,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/the-editors-roundtable-a-midyear-look-at-the-2026-life-sciences-industry/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/the-editors-roundtable-a-midyear-look-at-the-2026-life-sciences-industry.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Derisking CNS Drug Development With Tortugas Neuroscience's Jeff Jonas, M.D.","slug":"derisking-cns-drug-development-with-tortugas-neuroscience-s-jeff-jonas-m-d","published_at":"2026-06-01T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/derisking-cns-drug-development-with-tortugas-neuroscience-s-jeff-jonas-m-d","url":"https://www.buzzsprout.com/1011661/episodes/19248045-derisking-cns-drug-development-with-tortugas-neuroscience-s-jeff-jonas-m-d.mp3","duration_seconds":2992,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/derisking-cns-drug-development-with-tortugas-neuroscience-s-jeff-jonas-m-d/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/derisking-cns-drug-development-with-tortugas-neuroscience-s-jeff-jonas-m-d.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane","slug":"rare-disease-drug-commercialization-with-zevra-therapeutics-neil-mcfarlane","published_at":"2026-05-25T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/rare-disease-drug-commercialization-with-zevra-therapeutics-neil-mcfarlane","url":"https://www.buzzsprout.com/1011661/episodes/19208446-rare-disease-drug-commercialization-with-zevra-therapeutics-neil-mcfarlane.mp3","duration_seconds":3323,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/rare-disease-drug-commercialization-with-zevra-therapeutics-neil-mcfarlane/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/rare-disease-drug-commercialization-with-zevra-therapeutics-neil-mcfarlane.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Scaling Manufacturing For Personalized Cell Therapies With Cellino's Marinna Madrid, Ph.D.","slug":"scaling-manufacturing-for-personalized-cell-therapies-with-cellino-s-marinna-madrid-ph-d","published_at":"2026-05-18T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/scaling-manufacturing-for-personalized-cell-therapies-with-cellino-s-marinna-madrid-ph-d","url":"https://www.buzzsprout.com/1011661/episodes/19173171-scaling-manufacturing-for-personalized-cell-therapies-with-cellino-s-marinna-madrid-ph-d.mp3","duration_seconds":3055,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/scaling-manufacturing-for-personalized-cell-therapies-with-cellino-s-marinna-madrid-ph-d/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/scaling-manufacturing-for-personalized-cell-therapies-with-cellino-s-marinna-madrid-ph-d.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D.","slug":"building-a-new-antibody-discovery-platform-with-infinimmune-s-wyatt-mcdonnell-ph-d","published_at":"2026-05-11T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/building-a-new-antibody-discovery-platform-with-infinimmune-s-wyatt-mcdonnell-ph-d","url":"https://www.buzzsprout.com/1011661/episodes/19136686-building-a-new-antibody-discovery-platform-with-infinimmune-s-wyatt-mcdonnell-ph-d.mp3","duration_seconds":3252,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/building-a-new-antibody-discovery-platform-with-infinimmune-s-wyatt-mcdonnell-ph-d/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/building-a-new-antibody-discovery-platform-with-infinimmune-s-wyatt-mcdonnell-ph-d.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"From Partnered ASO Therapies To A Wholly-Owned Pipeline With Ionis's Brett Monia, Ph.D.","slug":"from-partnered-aso-therapies-to-a-wholly-owned-pipeline-with-ionis-s-brett-monia-ph-d","published_at":"2026-05-04T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/from-partnered-aso-therapies-to-a-wholly-owned-pipeline-with-ionis-s-brett-monia-ph-d","url":"https://www.buzzsprout.com/1011661/episodes/19096332-from-partnered-aso-therapies-to-a-wholly-owned-pipeline-with-ionis-s-brett-monia-ph-d.mp3","duration_seconds":3356,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/from-partnered-aso-therapies-to-a-wholly-owned-pipeline-with-ionis-s-brett-monia-ph-d/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/from-partnered-aso-therapies-to-a-wholly-owned-pipeline-with-ionis-s-brett-monia-ph-d.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary","slug":"implementing-a-new-ceo-strategy-with-nervgen-s-adam-rogers-m-d-and-rich-macary","published_at":"2026-04-27T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/implementing-a-new-ceo-strategy-with-nervgen-s-adam-rogers-m-d-and-rich-macary","url":"https://www.buzzsprout.com/1011661/episodes/19058777-implementing-a-new-ceo-strategy-with-nervgen-s-adam-rogers-m-d-and-rich-macary.mp3","duration_seconds":2857,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/implementing-a-new-ceo-strategy-with-nervgen-s-adam-rogers-m-d-and-rich-macary/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/implementing-a-new-ceo-strategy-with-nervgen-s-adam-rogers-m-d-and-rich-macary.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"The Impact Of FDA Risk On Biotech Rewards With CFO And Board Director Allan Shaw","slug":"the-impact-of-fda-risk-on-biotech-rewards-with-cfo-and-board-director-allan-shaw","published_at":"2026-04-20T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/the-impact-of-fda-risk-on-biotech-rewards-with-cfo-and-board-director-allan-shaw","url":"https://www.buzzsprout.com/1011661/episodes/19019921-the-impact-of-fda-risk-on-biotech-rewards-with-cfo-and-board-director-allan-shaw.mp3","duration_seconds":2813,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/the-impact-of-fda-risk-on-biotech-rewards-with-cfo-and-board-director-allan-shaw/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/the-impact-of-fda-risk-on-biotech-rewards-with-cfo-and-board-director-allan-shaw.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.","slug":"biosimilars-and-complex-medicines-for-all-with-rna-therapeutics-sarfaraz-niazi-ph-d","published_at":"2026-04-13T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/biosimilars-and-complex-medicines-for-all-with-rna-therapeutics-sarfaraz-niazi-ph-d","url":"https://www.buzzsprout.com/1011661/episodes/18988960-biosimilars-and-complex-medicines-for-all-with-rna-therapeutics-sarfaraz-niazi-ph-d.mp3","duration_seconds":3513,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/biosimilars-and-complex-medicines-for-all-with-rna-therapeutics-sarfaraz-niazi-ph-d/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/biosimilars-and-complex-medicines-for-all-with-rna-therapeutics-sarfaraz-niazi-ph-d.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor","slug":"radiotherapeutics-for-neuroendocrine-tumors-with-perspective-therapeutics-thijs-spoor","published_at":"2026-04-06T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/radiotherapeutics-for-neuroendocrine-tumors-with-perspective-therapeutics-thijs-spoor","url":"https://www.buzzsprout.com/1011661/episodes/18946349-radiotherapeutics-for-neuroendocrine-tumors-with-perspective-therapeutics-thijs-spoor.mp3","duration_seconds":2426,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/radiotherapeutics-for-neuroendocrine-tumors-with-perspective-therapeutics-thijs-spoor/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/radiotherapeutics-for-neuroendocrine-tumors-with-perspective-therapeutics-thijs-spoor.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Investing In Early-Stage Oncology With Yosemite's Dan McHugh","slug":"investing-in-early-stage-oncology-with-yosemite-s-dan-mchugh","published_at":"2026-03-30T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/investing-in-early-stage-oncology-with-yosemite-s-dan-mchugh","url":"https://www.buzzsprout.com/1011661/episodes/18905866-investing-in-early-stage-oncology-with-yosemite-s-dan-mchugh.mp3","duration_seconds":3341,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/investing-in-early-stage-oncology-with-yosemite-s-dan-mchugh/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/investing-in-early-stage-oncology-with-yosemite-s-dan-mchugh.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash","slug":"commercializing-car-t-cell-therapy-with-legend-biotech-s-alan-bash","published_at":"2026-03-23T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/commercializing-car-t-cell-therapy-with-legend-biotech-s-alan-bash","url":"https://www.buzzsprout.com/1011661/episodes/18874087-commercializing-car-t-cell-therapy-with-legend-biotech-s-alan-bash.mp3","duration_seconds":3057,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/commercializing-car-t-cell-therapy-with-legend-biotech-s-alan-bash/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/commercializing-car-t-cell-therapy-with-legend-biotech-s-alan-bash.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.","slug":"radiotherapeutics-for-cns-cancers-with-plus-therapeutics-marc-hedrick-m-d","published_at":"2026-03-16T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/radiotherapeutics-for-cns-cancers-with-plus-therapeutics-marc-hedrick-m-d","url":"https://www.buzzsprout.com/1011661/episodes/18828654-radiotherapeutics-for-cns-cancers-with-plus-therapeutics-marc-hedrick-m-d.mp3","duration_seconds":3240,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/radiotherapeutics-for-cns-cancers-with-plus-therapeutics-marc-hedrick-m-d/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/radiotherapeutics-for-cns-cancers-with-plus-therapeutics-marc-hedrick-m-d.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Developing Novel Cancer Drugs On A Budget With Iterion Therapeutics' Rahul Aras, Ph.D.","slug":"developing-novel-cancer-drugs-on-a-budget-with-iterion-therapeutics-rahul-aras-ph-d","published_at":"2026-03-09T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/developing-novel-cancer-drugs-on-a-budget-with-iterion-therapeutics-rahul-aras-ph-d","url":"https://www.buzzsprout.com/1011661/episodes/18788098-developing-novel-cancer-drugs-on-a-budget-with-iterion-therapeutics-rahul-aras-ph-d.mp3","duration_seconds":2910,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/developing-novel-cancer-drugs-on-a-budget-with-iterion-therapeutics-rahul-aras-ph-d/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/developing-novel-cancer-drugs-on-a-budget-with-iterion-therapeutics-rahul-aras-ph-d.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Making Biologics Orally Available With Vivtex's Thomas von Erlach, Ph.D.","slug":"making-biologics-orally-available-with-vivtex-s-thomas-von-erlach-ph-d","published_at":"2026-03-02T11:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/making-biologics-orally-available-with-vivtex-s-thomas-von-erlach-ph-d","url":"https://www.buzzsprout.com/1011661/episodes/18746013-making-biologics-orally-available-with-vivtex-s-thomas-von-erlach-ph-d.mp3","duration_seconds":3237,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/making-biologics-orally-available-with-vivtex-s-thomas-von-erlach-ph-d/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/making-biologics-orally-available-with-vivtex-s-thomas-von-erlach-ph-d.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"An Anthropological Lens On Leadership In Life Sciences With Bunka's Monika Sumra, Ph.D.","slug":"an-anthropological-lens-on-leadership-in-life-sciences-with-bunka-s-monika-sumra-ph-d","published_at":"2026-02-23T11:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/an-anthropological-lens-on-leadership-in-life-sciences-with-bunka-s-monika-sumra-ph-d","url":"https://www.buzzsprout.com/1011661/episodes/18705895-an-anthropological-lens-on-leadership-in-life-sciences-with-bunka-s-monika-sumra-ph-d.mp3","duration_seconds":3499,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/an-anthropological-lens-on-leadership-in-life-sciences-with-bunka-s-monika-sumra-ph-d/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/an-anthropological-lens-on-leadership-in-life-sciences-with-bunka-s-monika-sumra-ph-d.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Company Turnarounds And AI For Infectious Diseases With Seek Labs' Jared Bauer","slug":"company-turnarounds-and-ai-for-infectious-diseases-with-seek-labs-jared-bauer","published_at":"2026-02-16T11:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/company-turnarounds-and-ai-for-infectious-diseases-with-seek-labs-jared-bauer","url":"https://www.buzzsprout.com/1011661/episodes/18669074-company-turnarounds-and-ai-for-infectious-diseases-with-seek-labs-jared-bauer.mp3","duration_seconds":3416,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/company-turnarounds-and-ai-for-infectious-diseases-with-seek-labs-jared-bauer/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/company-turnarounds-and-ai-for-infectious-diseases-with-seek-labs-jared-bauer.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Bringing Curative Cell Therapies To Market with Kite Pharma's Cindy Perettie","slug":"bringing-curative-cell-therapies-to-market-with-kite-pharma-s-cindy-perettie","published_at":"2026-02-09T11:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/bringing-curative-cell-therapies-to-market-with-kite-pharma-s-cindy-perettie","url":"https://www.buzzsprout.com/1011661/episodes/18624039-bringing-curative-cell-therapies-to-market-with-kite-pharma-s-cindy-perettie.mp3","duration_seconds":2556,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/bringing-curative-cell-therapies-to-market-with-kite-pharma-s-cindy-perettie/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/bringing-curative-cell-therapies-to-market-with-kite-pharma-s-cindy-perettie.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"BoB@JPM: Brian Hilberdink, Boehringer Ingelheim","slug":"bob-jpm-brian-hilberdink-boehringer-ingelheim","published_at":"2026-02-02T11:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/bob-jpm-brian-hilberdink-boehringer-ingelheim","url":"https://www.buzzsprout.com/1011661/episodes/18584367-bob-jpm-brian-hilberdink-boehringer-ingelheim.mp3","duration_seconds":2675,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/bob-jpm-brian-hilberdink-boehringer-ingelheim/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/bob-jpm-brian-hilberdink-boehringer-ingelheim.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"BoB@JPM: Ron Cooper, enGene","slug":"bob-jpm-ron-cooper-engene","published_at":"2026-01-26T11:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/bob-jpm-ron-cooper-engene","url":"https://www.buzzsprout.com/1011661/episodes/18546471-bob-jpm-ron-cooper-engene.mp3","duration_seconds":3357,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/bob-jpm-ron-cooper-engene/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/bob-jpm-ron-cooper-engene.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"BoB@JPM: Marc Salzberg, M.D., Airway Therapeutics","slug":"bob-jpm-marc-salzberg-m-d-airway-therapeutics","published_at":"2026-01-19T11:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/bob-jpm-marc-salzberg-m-d-airway-therapeutics","url":"https://www.buzzsprout.com/1011661/episodes/18511357-bob-jpm-marc-salzberg-m-d-airway-therapeutics.mp3","duration_seconds":2168,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/bob-jpm-marc-salzberg-m-d-airway-therapeutics/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/bob-jpm-marc-salzberg-m-d-airway-therapeutics.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"A Royalty Model For Value Creation With Zymeworks' Kenneth Galbraith","slug":"a-royalty-model-for-value-creation-with-zymeworks-kenneth-galbraith","published_at":"2026-01-12T11:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/a-royalty-model-for-value-creation-with-zymeworks-kenneth-galbraith","url":"https://www.buzzsprout.com/1011661/episodes/18474370-a-royalty-model-for-value-creation-with-zymeworks-kenneth-galbraith.mp3","duration_seconds":3524,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/a-royalty-model-for-value-creation-with-zymeworks-kenneth-galbraith/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/a-royalty-model-for-value-creation-with-zymeworks-kenneth-galbraith.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Life Science Connect Editors' Roundtable: Wrapping Up 2025 And Looking Ahead","slug":"life-science-connect-editors-roundtable-wrapping-up-2025-and-looking-ahead","published_at":"2026-01-05T11:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/life-science-connect-editors-roundtable-wrapping-up-2025-and-looking-ahead","url":"https://www.buzzsprout.com/1011661/episodes/18427958-life-science-connect-editors-roundtable-wrapping-up-2025-and-looking-ahead.mp3","duration_seconds":4872,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/life-science-connect-editors-roundtable-wrapping-up-2025-and-looking-ahead/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/life-science-connect-editors-roundtable-wrapping-up-2025-and-looking-ahead.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Building Cell Therapy Companies With Kenai Therapeutics' Nick Manusos","slug":"building-cell-therapy-companies-with-kenai-therapeutics-nick-manusos","published_at":"2025-12-29T11:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/building-cell-therapy-companies-with-kenai-therapeutics-nick-manusos","url":"https://www.buzzsprout.com/1011661/episodes/18401996-building-cell-therapy-companies-with-kenai-therapeutics-nick-manusos.mp3","duration_seconds":2799,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/building-cell-therapy-companies-with-kenai-therapeutics-nick-manusos/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/building-cell-therapy-companies-with-kenai-therapeutics-nick-manusos.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Modernizing Clinical Trial Operations With Merck's Jennifer Sheller","slug":"modernizing-clinical-trial-operations-with-merck-s-jennifer-sheller","published_at":"2025-12-22T11:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/modernizing-clinical-trial-operations-with-merck-s-jennifer-sheller","url":"https://www.buzzsprout.com/1011661/episodes/18370798-modernizing-clinical-trial-operations-with-merck-s-jennifer-sheller.mp3","duration_seconds":3339,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/modernizing-clinical-trial-operations-with-merck-s-jennifer-sheller/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/modernizing-clinical-trial-operations-with-merck-s-jennifer-sheller.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Transforming Chronic Kidney Disease With ProKidney's Bruce Culleton, M.D.","slug":"transforming-chronic-kidney-disease-with-prokidney-s-bruce-culleton-m-d","published_at":"2025-12-15T11:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/transforming-chronic-kidney-disease-with-prokidney-s-bruce-culleton-m-d","url":"https://www.buzzsprout.com/1011661/episodes/18342901-transforming-chronic-kidney-disease-with-prokidney-s-bruce-culleton-m-d.mp3","duration_seconds":3336,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/transforming-chronic-kidney-disease-with-prokidney-s-bruce-culleton-m-d/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/transforming-chronic-kidney-disease-with-prokidney-s-bruce-culleton-m-d.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Engineering B Cells With Immusoft's Sean Ainsworth","slug":"engineering-b-cells-with-immusoft-s-sean-ainsworth","published_at":"2025-12-08T11:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/engineering-b-cells-with-immusoft-s-sean-ainsworth","url":"https://www.buzzsprout.com/1011661/episodes/18292145-engineering-b-cells-with-immusoft-s-sean-ainsworth.mp3","duration_seconds":3231,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/engineering-b-cells-with-immusoft-s-sean-ainsworth/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/engineering-b-cells-with-immusoft-s-sean-ainsworth.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Building A Cancer Pipeline In A Molecule With Actuate Therapeutics' Dan Schmitt","slug":"building-a-cancer-pipeline-in-a-molecule-with-actuate-therapeutics-dan-schmitt","published_at":"2025-12-01T11:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/building-a-cancer-pipeline-in-a-molecule-with-actuate-therapeutics-dan-schmitt","url":"https://www.buzzsprout.com/1011661/episodes/18250776-building-a-cancer-pipeline-in-a-molecule-with-actuate-therapeutics-dan-schmitt.mp3","duration_seconds":3085,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/building-a-cancer-pipeline-in-a-molecule-with-actuate-therapeutics-dan-schmitt/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/building-a-cancer-pipeline-in-a-molecule-with-actuate-therapeutics-dan-schmitt.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Biotech Collaboration Strategy With IGI's Cyril Konto, M.D.","slug":"biotech-collaboration-strategy-with-igi-s-cyril-konto-m-d","published_at":"2025-11-24T11:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/biotech-collaboration-strategy-with-igi-s-cyril-konto-m-d","url":"https://www.buzzsprout.com/1011661/episodes/18217716-biotech-collaboration-strategy-with-igi-s-cyril-konto-m-d.mp3","duration_seconds":3521,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/biotech-collaboration-strategy-with-igi-s-cyril-konto-m-d/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/biotech-collaboration-strategy-with-igi-s-cyril-konto-m-d.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}]}